Acute Fish Oil supplementation and Aspirin treatment modulates lipid profile in Platelet Rich Plasma: a randomized pilot trial

Authors

Joshua M. Morriss, Virginia Commonwealth University, School of PharmacyFollow
Lisa A. Turner, Virginia Commonwealth University, School of Dentistry
Danielle M. McCormack, Virginia Commonwealth University, School of Dentistry
Daniel Contaifer, Virginia Commonwealth University, School of Pharmacy
Naren Gajenthra Kumar, University of California, Berkeley
Saidheeraj Paravataneni, Virginia Commonwealth Unviersity
Monther Alsultan, Virginia Commonwealth University, School of Pharmacy
Suad Alshammari, Virginia Commonwealth University, School of Pharmacy
Silas Contaifer, Virginia Commonwealth University, School of Pharmacy
Parthasarathy Madurantakam, Virginia Commonwealth University, School of Dentistry
Dayanjan Wijesinghe, Virginia Commonwealth University, School of Pharmacy

Document Type

Poster

Original Publication Date

2021

Date of Submission

April 2021

Abstract

Aims: Platelet rich plasma (PRP) has been used in tissue repair to treat numerous inflammatory pathophysiologies. Recent studies have elucidated that the bioactive lipid fraction of PRP significantly contributes towards the resolution of inflammation. There has been great interest in how therapeutics could modulate the PRP lipidome to formulate a more pro-resolving matrix. Many of the pathways used to produce either pro-resolving or pro-inflammatory lipids are shared between ω-3 and ω-6 polyunsaturated fatty acids (PUFA). Here, we explored the separate and interacting effects acute exogenous ω-3 PUFA supplementation and aspirin had on the lipidome of PRP within 6 hours.

Methods:PRP from 45 patients was obtained at baseline and after 6-hours from either control or those receiving one 1400 mg fish oil tablet, Bayer low-dose aspirin (81mg), or combinational therapy. Lipids were acquired by liquid chromatography mass spectrometry. Spearman rank correlation analysis visually assessed what effects treatments had on the relative abundance of PUFA derivatives. The control group was referenced for lipid selection across groups; lipids were selected on the basis that they significantly (p

Results: Fish oil ω-3 PUFA supplementation and aspirin had separate and interacting effects on oxylipin and neutral lipid correlations. Strongly correlated (rho > 0.65) ω-6 PUFA metabolites were reversed or reduced in magnitude following either treatment. A total of 24 lipid species were significantly modulated in the fish oil treatment group, with notable (p4), and lipoxin A4 (LXA₄).

Conclusion: We can confirm that fish oil supplementation and aspirin do exert modulatory effects on the lipid fraction of PRP within a short period of time (6-hours). The PUFAs composing fish oil impacted a wide range of the lipidome – possibly though a mechanism of ω-3/ω-6 enzymatic competition. Our results support that ω-3 PUFA supplementation may improve the efficacy of PRP for short-term use.

Is Part Of

VCU Pharmacotherapy and Outcomes Science Publications